The influence of lifestyle factors on serum etonogestrel concentrations among contraceptive implant users

Aaron Lazorwitz; Jeanelle Sheeder; Stephanie Teal

doi:10.1016/j.contraception.2024.110539

The influence of lifestyle factors on serum etonogestrel concentrations among contraceptive implant users

Contraception. 2024 Jul 11:110539. doi: 10.1016/j.contraception.2024.110539. Online ahead of print.

Authors

Aaron Lazorwitz¹, Jeanelle Sheeder², Stephanie Teal³

Affiliations

¹ University of Colorado Anschutz Medical Campus, Department of Obstetrics and Gynecology, Division of Family Planning, Aurora, CO, USA. Electronic address: aaron.lazorwitz@yale.edu.
² University of Colorado Anschutz Medical Campus, Department of Obstetrics and Gynecology, Division of Family Planning, Aurora, CO, USA.
³ University Hospitals Cleveland Medical Center and Case Western Reserve University, Department of Obstetrics and Gynecology, Cleveland, OH, USA.

PMID: 39002624
DOI: 10.1016/j.contraception.2024.110539

Abstract

Objective: To evaluate how diet, exercise, and substance use influence serum etonogestrel concentrations among contraceptive implant users.

Study design: We conducted a cross-sectional analysis of healthy, reproductive-age etonogestrel implant users. We assessed participants' current diet, exercise, and substance (alcohol, tobacco, marijuana) use habits while simultaneously measuring serum etonogestrel concentrations. We used linear modeling to test for associations between survey responses and etonogestrel concentrations.

Results: Among 115 participants, exercise habits and substance use had no significant associations with etonogestrel concentrations, while increased caloric intake demonstrated inconsistent associations.

Conclusion: The lifestyle factors of diet, exercise, and substance use do not influence steady-state pharmacokinetics among contraceptive implant users.

Clinical trial registration: Clinicaltrials.gov, NCT03092037.

Keywords: Contraceptive implant; Diet; Etonogestrel; Exercise; Lifestyle; Marijuana.

Associated data

ClinicalTrials.gov/NCT03092037